FDA Oncology Wave Q1 2026: Eight Approvals Reshape Manufacturing Readiness

FDA's oncology and hematology approval activity in Q1 2026 has placed immediate pressure on manufacturing sites, QA functions, and regulatory affairs teams to align labeling, combination product logistics, and process validation documentation across a broad range of modalities. Eight distinct actions spanning small molecules, biologics, and subcutaneous formulations now require coordinated readiness across supply chains that were not necessarily built for combination regimens.

Among the most operationally complex approvals: on March 5, 2026, FDA approved teclistamab (Tecvayli, Janssen Biotech) in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma in adults who received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. On March 20, 2026, nivolumab (Opdivo, Bristol Myers Squibb) received approval with AVD chemotherapy for previously untreated Stage III or IV classical Hodgkin lymphoma in adults and pediatric patients 12 years and older. On March 25, 2026, relacorilant (Lifyorli, Corcept Therapeutics), a glucocorticoid receptor antagonist, was approved with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who received one to three prior systemic regimens, at least one including bevacizumab.

Earlier in the quarter, FDA granted traditional approval to encorafenib (Braftovi, Array BioPharma/Pfizer) on February 24, 2026, in combination with cetuximab and fluorouracil-based chemotherapy for metastatic colorectal cancer with a BRAF V600E mutation as detected by an FDA-authorized test. Encorafenib had previously received accelerated approval with cetuximab and mFOLFOX6 for the same indication in 2024. On February 26, 2026, zongertinib (Hernexeos, Boehringer Ingelheim) received accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations, also requiring detection by an FDA-authorized test. Acalabrutinib (Calquence, AstraZeneca) tablets and capsules were approved February 19, 2026, in combination with venetoclax for CLL or SLL. On February 10, 2026, pembrolizumab (Keytruda, Merck) and its subcutaneous formulation with berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) were approved with paclitaxel, with or without bevacizumab, for platinum-resistant ovarian carcinomas expressing PD-L1 (CPS greater than or equal to 1).

For QA directors and plant heads, the companion diagnostic requirements attached to zongertinib, encorafenib, and pembrolizumab approvals signal that labeling control procedures must account for FDA-authorized test linkage. Combination biologic regimens such as teclistamab plus daratumumab hyaluronidase-fihj introduce cold-chain and sterility assurance coordination obligations that extend beyond a single manufacturing authorization. The acalabrutinib approval covering both tablet and capsule dosage forms also warrants a review of site-specific 21 CFR Part 211 documentation to confirm both presentations are covered under current validated processes. FDA notes it does not issue approval announcements for every oncology or hematology approval or drug label update, and directs stakeholders to Drugs@FDA for current prescribing information.